TruSight Tumor 26

TruSight Tumor 26

The TruSight Tumor sequencing panel takes a deeper view of variation in solid tumors including lung, colon, melanoma, gastric, and ovarian. This kit enables clinical researchers to identify low-frequency variation across 26 genes for a more comprehensive view of somatic variation. Low limit of detection of FFPE samples is obtained by creating two libraries per sample: one for the forward strand and one for the reverse strand. Illumina recommends running 4 samples (8 libraries) per MiSeq v2 run to obtain a minimum coverage of 1000x per amplicon.

Catalog ID(s)
FC-130-2001, TG-130-2001 (48 Samples)

*TG-labeled consumables include features intended to help customers reduce the frequency of revalidation. They are available only under supply agreement and require customers to provide a binding forecast. Contact your account manager for more information.

Order Now Support

TruSight Tumor Gene List

AKT1 ALK
FGFR2 APC
FOXL2 BRAF
GNAQ CDH1 CTNNB1 EGFR ERBB2 FBXW7 GNAS KIT
PTEN KRAS
SMAD4 MAP2K1
SRC MET MSH6 NRAS PDGFRA PIK3CA STK11 TP53

Please rotate your device for details

* Library prep is compatible with all Illumina instruments. Recommended instruments chosen based on typical output and analysis need for selected application.
† Based on > 1,000x per amplicon.
Project Recommendations
Species Compatibility Human
Recommended Illumina Instrument* MiniSeq MiSeq
Recommended Samples per run† 2 6 4 (v2 chemistry)
Run Mode Mid Output High Output -
Max Recommended Read Length Up to 2x121 bp Up to 2x121 bp Up to 2x121 bp
Recommended Secondary Analysis
  • Local Run Manager Amplicon DS
  • BaseSpace Amplicon DS
  • MiSeq Reporter AmpliconDS Workflow
Recommended Down Stream Analysis VariantStudio
Order Now Support
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.